Hence, the higher TP53 mutation rates in the cancers with higher PLK1 expression levels may also be partly responsible for the depressed tumor immunity in these cancers (Figure 8(a)) since a prior study has demonstrated that wildtype p53 could promote tumor immunity [25]. This evidence concerns the gene TP53 and cancer.